Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

Zoetis (ZTS) is anticipated to report Q3 2025 earnings on November 4th, with consensus estimates at $2.41 billion in revenue and $1.62 EPS, and is predicted to surpass these expectations. The projected beat is largely attributed to strong sales of key companion animal products like Simparica Trio, Apoquel, and Cytopoint across both U.S. and International segments, further boosted by recent label expansions. This positive momentum is expected to be partially mitigated by potential U.S. sales declines for osteoarthritis drugs Librela and Solensia due to side effect concerns, and reduced livestock product revenue following recent divestitures. The company's consistent track record of exceeding earnings estimates, with an average surprise of 6.19% over the past four quarters, supports the optimistic outlook.

Analysis

Zoetis (ZTS) is poised to report Q3 2025 earnings on November 4th, with consensus revenue and EPS estimates at $2.41 billion and $1.62, respectively. The company is widely projected to beat these expectations, supported by a positive Earnings ESP of +0.32% and a Zacks Rank #3, aligning with its consistent track record of exceeding estimates in the past four quarters by an average of 6.19%. In the last reported quarter, the company delivered an earnings surprise of 8.64%.

This anticipated beat is primarily driven by strong performance in companion animal products, particularly Simparica Trio, Apoquel, and Cytopoint, which are expected to boost both U.S. and International segment revenues. Recent label expansions for Apoquel and Simparica Trio are set to provide further sales momentum in upcoming quarters. However, potential U.S. sales declines for osteoarthritis drugs Librela and Solensia, due to reported side effect concerns, and reduced livestock product revenue following the October 2024 divestiture of certain assets, will partially offset these gains.

Despite the positive earnings outlook, ZTS shares have underperformed year-to-date, declining 10.8% against the industry's 9.2% growth. This divergence suggests that while operational execution remains strong, broader market or sector-specific pressures may be influencing investor sentiment, potentially setting up a post-earnings reaction.

Key Decisions for Investors

• Investors should monitor the magnitude of the expected earnings beat and management's commentary on the balance between strong companion animal product growth and headwinds from OA drug sales and livestock divestitures
• Consider potential short-term volatility given the stock's year-to-date underperformance despite strong operational execution
• Evaluate the long-term implications of recent product label expansions for Simparica Trio and Apoquel as key drivers for sustained revenue growth